Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$93.47−4.16 (-4.26%)
Close on Nov 20, 2026Market cap $8.24BP/E –Yield –
Spyre Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Spyre Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2025 it was $0. The highest annual figure on record is $18.74M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $886.00K | -62.0% |
| FY2022 | Dec 31, 2022 | $2.33M | -87.6% |
| FY2021 | Dec 31, 2021 | $18.74M | – |
| FY2020 | Dec 31, 2020 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $3.89M | -25.3% |
| FY2017 | Dec 31, 2017 | $5.21M | +12.5% |
| FY2016 | Dec 31, 2016 | $4.63M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $688.00K | +10.1% |
| Q1 FY2023 | Mar 31, 2023 | $198.00K | -85.5% |
| Q4 FY2022 | Dec 31, 2022 | $168.00K | -95.4% |
| Q3 FY2022 | Sep 30, 2022 | $174.00K | -87.6% |
| Q2 FY2022 | Jun 30, 2022 | $625.00K | -95.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.36M | – |
| Q4 FY2021 | Dec 31, 2021 | $3.64M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.40M | – |
| Q2 FY2021 | Jun 30, 2021 | $13.70M | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $0 | -100.0% |
| Q4 FY2018 | Dec 31, 2018 | $0 | -100.0% |
| Q3 FY2018 | Sep 30, 2018 | $0 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.38M | +60.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.51M | +53.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.48M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.26M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.48M | – |
| Q1 FY2017 | Mar 31, 2017 | $982.00K | – |
See a number that looks wrong?